Abstract
Background: One of the most important causes of death in the modern lifestyle is acute ischemic stroke, which is related to thrombosis in the blood vessels. Staphylokinase (SAK), a fibrinolytic agent, which is produced mainly by Staphylococcus aureus, is an indirect activator of plasminogen and belongs to the third generation of fibrinolytic enzymes.
Methods: Considering the very low level of production and immunogenicity concerns of natural SAK produced by Staphylococcus aureus, attempts have been made to produce recombinant SAKs with high production levels, more fibrinolytic activities and low immunogenicity.
Results and Conclusion: In this review, we summarized a number of expression systems based on recombinant DNA technology and protein-engineering approaches, which have been developed for the production of engineered recombinant SAK molecules with higher fibrinolytic activities and lower antigenicity.
Keywords: Staphylokinase, fibrinolytics, recombinant, thrombolysis, immunogenicity, plasminogen.
Graphical Abstract
Current Pharmaceutical Biotechnology
Title:Staphylokinase Enzyme: An Overview of Structure, Function and Engineered Forms
Volume: 18 Issue: 13
Author(s): Bahareh Vakili, Navid Nezafat, Manica Negahdaripour, Maryam Yari, Bijan Zare and Younes Ghasemi*
Affiliation:
- Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz,Iran
Keywords: Staphylokinase, fibrinolytics, recombinant, thrombolysis, immunogenicity, plasminogen.
Abstract: Background: One of the most important causes of death in the modern lifestyle is acute ischemic stroke, which is related to thrombosis in the blood vessels. Staphylokinase (SAK), a fibrinolytic agent, which is produced mainly by Staphylococcus aureus, is an indirect activator of plasminogen and belongs to the third generation of fibrinolytic enzymes.
Methods: Considering the very low level of production and immunogenicity concerns of natural SAK produced by Staphylococcus aureus, attempts have been made to produce recombinant SAKs with high production levels, more fibrinolytic activities and low immunogenicity.
Results and Conclusion: In this review, we summarized a number of expression systems based on recombinant DNA technology and protein-engineering approaches, which have been developed for the production of engineered recombinant SAK molecules with higher fibrinolytic activities and lower antigenicity.
Export Options
About this article
Cite this article as:
Vakili Bahareh , Nezafat Navid, Negahdaripour Manica , Yari Maryam, Zare Bijan and Ghasemi Younes *, Staphylokinase Enzyme: An Overview of Structure, Function and Engineered Forms, Current Pharmaceutical Biotechnology 2017; 18 (13) . https://dx.doi.org/10.2174/1389201019666180209121323
DOI https://dx.doi.org/10.2174/1389201019666180209121323 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
AMPK Function in Aging Process
Current Drug Targets Emergence of a New Zoonotic COVID-19 that Creates a Pandemic: Update on Current Pharmacotherapeutics and Future Prospective of Plasma Therapy
Coronaviruses Testosterone Deficiency in Male: A Risk Factor for Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs
Current Vascular Pharmacology Collagen-Binding Integrins as Pharmaceutical Targets
Current Pharmaceutical Design Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Ras Family Small GTPase-Mediated Neuroprotective Signaling in Stroke
Central Nervous System Agents in Medicinal Chemistry 5-HT3 Receptors: A Potential Therapeutic Target for Epilepsy
Current Neuropharmacology Adiponectin: A Key Player in Obesity Related Disorders
Current Pharmaceutical Design Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets The Relationship Between Personality Types and Sexual Dysfunction
Current Women`s Health Reviews Hypoxia as an Initiator of Neuroinflammation: Microglial Connections
Current Neuropharmacology Recent Advances in Drug Delivery: Potential and Limitations of Carbon Nanotubes
Recent Patents on Drug Delivery & Formulation Analysis of Adverse Events Related to 720 Cases of Neural Progenitor Cell Transplantation
CNS & Neurological Disorders - Drug Targets Hematological Parameters as Prognostic Biomarkers in Patients with Cardiovascular Diseases
Current Cardiology Reviews Scaffold Hopping Strategy for the Design, Synthesis and Biological Activity Evaluation of Novel Hexacyclic Scutellarein Derivatives with a 1,3-Oxazine Ring Fused at A-ring
Medicinal Chemistry Moving to the Rhythm with Clock (Circadian) Genes, Autophagy, mTOR, and SIRT1 in Degenerative Disease and Cancer
Current Neurovascular Research Structural Alterations of the Retinal Microcirculation in the “Prehypertensive” High- Normal Blood Pressure State
Current Pharmaceutical Design 2015 Update of Erectile Dysfunction Management Following Radical Prostatectomy: From Basic Research to Clinical Management
Current Pharmaceutical Design Evaluation of Blood Pressure Control using a New Arterial Stiffness Parameter, Cardio-ankle Vascular Index (CAVI)
Current Hypertension Reviews